Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) welcomes a decision by the World Health Organization (WHO) to add primary anti-infective candidate, RECCE® 327 (R327), to its list of Antibacterial Agents in Clinical Development and Preclinical Development.
The WHO report covers traditional and non-traditional antibacterial agents in development globally, evaluating to what extent the present pipeline addresses infections caused by priority pathogens, based on the updated 2024 WHO bacterial priority pathogens list.
R327 has been defined by the WHO as an ATP production disruptor and is the only compound under this category.
Tackling life-threatening and resistant bacteria
“We are pleased that R327 has been included in the list of antibacterial products aimed at tackling the urgent global health threat posed by antibiotic resistance,” Recce Pharmaceuticals CEO James Graham said.
“There is a demand for new antibiotic therapies and this report further showcases R327’s potential as a novel treatment for a broad range of life-threatening and resistant bacteria.”
ATP is the source of energy at the cellular level. Disrupting its production – as R327 has been identified to do – offers the potential to combat Gram-positive and Gram-negative pathogens.
About R327
Recce is developing R327 as an intravenous and topical therapy for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms.
The US FDA gas granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval.
R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.